World Pneumonia Day, every November 12, is a time to focus on the infection's persistent global impact and prioritize advancing patient care. Awareness days are excellent opportunities to review the latest currently recruiting clinical trials. So, for today, we're featuring currently recruiting clinical trials for community-acquired pneumonia (CAP).

The following are five of the most recent clinical trials on CAP that are currently recruiting in the United States.

Comparison Table for Five Currently Recruiting Clinical Trials on CAP
Study TitlePhaseEstimated EnrollmentStart DateEstimated Completion
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community-Acquired Pneumonia (ATTACC-CAP)34000October 2023March 2028
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-Acquired Pneumonia (sCAP) (ESsCAPE)3590September 2023October 2026
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)320000April 2016February 2026
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community-Acquired Pneumonia Treated With Beta-lactams (AD-CAP)41120September 2025September 2030
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP4236August 2024May 2027
Clinical Trials Rundown for Currently Recruiting CAP Trials

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community-Acquired Pneumonia (ATTACC-CAP)

  • Sponsor: University of Manitoba
  • Goal: Compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community-acquired pneumonia (CAP).
  • Intervention: Heparin
  • Primary Outcome Measure: Ordinal endpoint reflecting survival
  • Timeframe: 30 days
  • Study Details
  • Source

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-Acquired Pneumonia (sCAP) (ESsCAPE)

  • Sponsor: Biotest
  • Goal: The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation.
  • Interventions: Trimodulin, placebo (human albumin 1%)
  • Primary Outcome Measure: 28-day all-cause mortality rate
  • Timeframe: Between days 1-29
  • Study Details
  • Source

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)

  • Sponsor: UMC Utrecht
  • Goal: To evaluate the effect of a range of interventions to improve the outcome of patients admitted to intensive care with community-acquired pneumonia.
  • Interventions: More than 60 interventions are listed. View the complete list, here.
  • Primary Outcome Measures: All-cause mortality; Days alive and not receiving organ support in ICU.
  • Timeframes: Day 90; Day 21.
  • Study Details
  • Source

Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community-Acquired Pneumonia Treated With Beta-lactams (AD-CAP)

  • Sponsor: Mayo Clinic
  • Goal: The purpose of this study is to compare effectiveness and safety of Azithromycin versus Doxycycline in adult patients hospitalized with community-acquired pneumonia (CAP) treated with Beta-lactams.
  • Interventions: Doxycycline, azithromycin
  • Primary Outcome Measure: Hospital-free days
  • Timeframe: 28 days
  • Study Details
  • Source

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

  • Sponsor: Medical College of Wisconsin
  • Goal: To compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized children aged 3 months to 18 years, with uncomplicated community-acquired pneumonia.
  • Interventions: Ampicillin for injection, ceftriaxone for injection, amoxicillin, ampicillin / sulbactam injection, amoxicillin-clavulanate, clindamycin, cefprozil, levofloxacin
  • Primary Outcome Measure: Treatment failure rate
  • Timeframe: 14 days from the first dose of antibiotics
  • Study Details
  • Source
Related Guidelines:

Sign up for alerts and stay informed on the latest published guidelines.

Copyright © 2025 Guideline Central, all rights reserved.